Altimmune, Inc.
General ticker "ALT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $438.1M (TTM average)
Altimmune, Inc. does not follow the US Stock Market performance with the rate: -20.3%.
Estimated limits based on current volatility of 3.0%: low 2.27$, high 2.41$
Factors to consider:
- Total employees count: 57 (-3.4%) as of 2025
- Top business risk factors: Significant losses, Clinical trial failure, Regulatory and compliance, Manufacturing issues, Market competition
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.43$, 6.15$]
- 2026-12-31 to 2027-12-31 estimated range: [2.55$, 6.34$]
Financial Metrics affecting the ALT estimates:
- Positive: with PPE of -3.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: 69.38 < Shareholder equity ratio, % of 80.34 <= 81.92
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -23.94
- Positive: -40.59 < Investing cash flow per share per price, % of -39.16
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ALT quotes
Long-term ALT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.43MM | $0.02MM | $0.04MM |
| Operating Expenses | $96.36MM | $103.19MM | $94.53MM |
| Operating Income | $-95.93MM | $-103.17MM | $-94.49MM |
| Non-Operating Income | $7.48MM | $8.11MM | $5.71MM |
| Interest Expense | $0.04MM | $0.01MM | $1.64MM |
| R&D Expense | $65.80MM | $82.23MM | $66.43MM |
| Income(Loss) | $-88.45MM | $-95.06MM | $-88.77MM |
| Taxes | $0.00MM | $0.00MM | $-0.68MM |
| Net Income(Loss)* | $-88.45MM | $-95.06MM | $-88.09MM |
| Stockholders Equity | $194.10MM | $123.51MM | $224.89MM |
| Assets | $210.64MM | $139.31MM | $279.93MM |
| Operating Cash Flow | $-75.81MM | $-79.85MM | $-67.53MM |
| Capital expenditure | $0.05MM | $0.00MM | $0.01MM |
| Investing Cash Flow | $13.73MM | $-28.39MM | $-132.47MM |
| Financing Cash Flow | $86.11MM | $10.04MM | $206.84MM |
| Earnings Per Share** | $-1.66 | $-1.34 | $-1.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.